Actively Recruiting
Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol
Led by West China Hospital · Updated on 2026-01-06
1300
Participants Needed
1
Research Sites
378 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Percutaneous coronary intervention (PCI) is an important treatment strategy for patients with coronary artery disease. Combined bleeding after PCI significantly increases the risk of death in patients. The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk (HBR) after PCI has been a hot topic in cardiovascular research. There is no accepted prognostic model or recommended antiplatelet therapy for patients with PCI-HBR. In this project, based on retrospective data extraction and prospective database building, we used artificial intelligence (AI) to analyze the adverse prognostic predictors of PCI-HBR patients, observe the types of antiplatelet drugs and duration of dual antiplatelet therapy in PCI-HBR patients, and compare the safety and feasibility of different antiplatelet regimens and treatment courses. The safety and feasibility of different antiplatelet regimens and regimens were compared.
CONDITIONS
Official Title
Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- PCI patients older than 18 years
- Meet at least 1 major or 2 minor criteria of the ARC-HBR
- Major ARC-HBR criteria include long-term oral anticoagulant use, severe or end-stage chronic kidney disease (eGFR <30 ml/min/1.73m2), hemoglobin <11 g/dl, spontaneous bleeding requiring hospitalization or transfusion within past 6 months or any time, chronic bleeding conditions, cirrhosis with portal hypertension, moderate to severe thrombocytopenia (platelets <100x10^9/L), active malignancy within past 12 months (except non-melanoma skin cancer), previous spontaneous brain hemorrhage, traumatic brain hemorrhage within past 12 months, moderate or severe ischemic stroke within past 6 months, cerebral arteriovenous malformation, recent major surgery or trauma within 30 days prior to PCI, or major non-delayable surgery during dual antiplatelet therapy
- Secondary criteria include age 75 years or older, moderate chronic kidney disease (eGFR 30-59 ml/min/1.73m2), hemoglobin 11-13 g/dl in men or 11-12 g/dl in women, spontaneous bleeding requiring hospitalization or transfusion within past 6 to 12 months, long-term use of oral NSAIDs or steroids, and any duration ischemic stroke not covered by primary criteria
You will not qualify if you...
- Patients who were already bleeding at baseline inclusion
- Patients unable to be followed up for major adverse cardiovascular events due to contact issues or other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital, Sichuan University
Sichuan, Sichuan, China, 610041
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here